 |
|
Scripps research team defines new painkilling chemical pathway
November 24, 2008Discovery could lead to new pain treatments
Marijuana kills pain by activating a set of proteins known as cannabinoid receptors, which can also regulate appetite, inflammation, and memory. The body also has chemicals known as endocannabinoids that naturally activate these same receptors, namely N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG). These natural components of the cannabinoid system remain the focus of intense efforts to develop new treatments not only for chronic pain, but also for obesity, anxiety, and depression. However, until the new paper, specific methods to study 2-AG signaling have been lacking.
AEA's activity has been well understood for years. In past research, Cravatt and his team identified an enzyme called fatty acid amide hydrolase, or FAAH, that breaks down AEA, effectively reducing its pain killing activity. A number of compounds are now in clinical development that target and breakdown FAAH, allowing AEA to build up, reducing pain. However, FAAH does not control 2-AG metabolism in vivo, and therefore, the potential biological functions and therapeutic potential of this second endocannabinoid have remained largely unknown.
Teasing out 2-AG's specific impacts have proven challenging. Comparable to FAAH, an enzyme called monoacylglycerol lipase (MAGL) breaks down 2-AG. But, despite numerous attempts, no group had been able to develop a chemical that inhibits MAGL specifically.
"The tools-selective and efficacious MAGL inhibitors-just weren't there, " says Jonathan Long, a graduate student of the Scripps Research Kellogg School of Science and Technology who is a member of the Cravatt lab and a first author of the new paper.
But now, a MAGL-specific inhibitor is finally available, thanks to the lab's new work. Key to this success was Activity-Based Protein Profiling, a unique chemical technique the group devised and has used fruitfully in other inhibitor hunts. This system enables the rapid engineering and testing of chemical compounds against many members of enzyme families, in hope of finding effective and selective inhibitors.
For this project, the group developed about 200 compounds and found that one was a highly effective block for MAGL. The scientists dubbed the compound JZL184, named after Long's initials and the order in the series of potential inhibitors tested. JZL184 effectively blocks only MAGL among more than 40 related brain enzymes, which opened the door for the first definitive study of 2-AG's activity.
A New View of 2-AG
Unlike increased AEA, which causes only reduced pain sensation, the team found that MAGL inhibition using JZL184, and the resulting increase in 2-AG concentration, not only reduced pain in mice, but also induced other effects associated with the cannabinoid receptors, namely hypothermia and decreased movement.
"This really does suggest a sort of segregation of labor, if you will," says Cravatt of the differential effects of elevating AEA versus 2-AG as part of the overall function of the cannabinoid system. "That, I think, is a truly unique result."
While treatments based on inhibiting FAAH show great promise for controlling pain, manipulating MAGL levels could also be a boon for treatment development, especially if 2-AG's other effects, such as hypothermia, can be managed.
"There are so many different types of pain," Cravatt says, "that it's possible some types could be more effectively treated with one treatment than another."
Scripps Research Institute
Teasing out 2-AG's specific impacts have proven challenging. Comparable to FAAH, an enzyme called monoacylglycerol lipase (MAGL) breaks down 2-AG. But, despite numerous attempts, no group had been able to develop a chemical that inhibits MAGL specifically.
"The tools-selective and efficacious MAGL inhibitors-just weren't there, " says Jonathan Long, a graduate student of the Scripps Research Kellogg School of Science and Technology who is a member of the Cravatt lab and a first author of the new paper.
But now, a MAGL-specific inhibitor is finally available, thanks to the lab's new work. Key to this success was Activity-Based Protein Profiling, a unique chemical technique the group devised and has used fruitfully in other inhibitor hunts. This system enables the rapid engineering and testing of chemical compounds against many members of enzyme families, in hope of finding effective and selective inhibitors.
For this project, the group developed about 200 compounds and found that one was a highly effective block for MAGL. The scientists dubbed the compound JZL184, named after Long's initials and the order in the series of potential inhibitors tested. JZL184 effectively blocks only MAGL among more than 40 related brain enzymes, which opened the door for the first definitive study of 2-AG's activity.
A New View of 2-AG
Unlike increased AEA, which causes only reduced pain sensation, the team found that MAGL inhibition using JZL184, and the resulting increase in 2-AG concentration, not only reduced pain in mice, but also induced other effects associated with the cannabinoid receptors, namely hypothermia and decreased movement.
"This really does suggest a sort of segregation of labor, if you will," says Cravatt of the differential effects of elevating AEA versus 2-AG as part of the overall function of the cannabinoid system. "That, I think, is a truly unique result."
While treatments based on inhibiting FAAH show great promise for controlling pain, manipulating MAGL levels could also be a boon for treatment development, especially if 2-AG's other effects, such as hypothermia, can be managed.
"There are so many different types of pain," Cravatt says, "that it's possible some types could be more effectively treated with one treatment than another."
Scripps Research Institute
Cannabinoid Current Events and Cannabinoid News RSSImpact of cannabis on bones changes with age, study finds
Scientists investigating the effects of cannabis on bone health have found that its impact varies dramatically with age.
Marijuana use linked to increased risk of testicular cancer
Frequent and/or long-term marijuana use may significantly increase a man's risk of developing the most aggressive type of testicular cancer, according to a study by researchers at Fred Hutchinson Cancer Research Center. The study results were published online Feb. 9 in the journal Cancer.
New cannabis-like drugs could block pain without affecting brain, says study
A new type of drug could alleviate pain in a similar way to cannabis without affecting the brain, according to a new study published in the journal Pain on Monday 15 September.
Milestone for cannabinoid MS study
The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.
Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Opioids and cannabinoids influence mobility of spermatozoids
A PhD thesis from the University of the Basque Country has concluded that there are opioid and cannabinoid receptors in human sperm and that these influence the mobility of spermatozoid.
Medicines derived from cannabis: a review of adverse events
Researchers at the McGill University Health Centre (MUHC), McGill University and the University of British Columbia (UBC) determined that medical use of cannabinoids do not cause an increase in serious adverse events, but are associated with an increase in some non-serious adverse events.
New Mount Sinai research tracks effects of addictive drugs on brain
Mount Sinai researchers may have unlocked the key to better understanding the effect addictive drugs have on the human brain.
U of Minnesota researcher discovers the starting point of sun-induced skin cancer
According to a new study from the University of Minnesota, the earliest event in the development of sun-induced skin cancer may have been identified.
Study finds possible connection between marijuana abuse and stroke or heart attacks
Long-term harmful effects of marijuana (MJ) include risk for heart attacks and strokes in addition to impaired learning and memory. The active chemical in MJ called delta-9-tetrahyrdocannabinol (THC) is believed to exert these effects by binding to cannabinoid (CB) receptors located on several cell types in various organs.
More Cannabinoid Current Events and Cannabinoid News Articles
 |
Cannabinoids (Handbook of Experimental Pharmacology) (Volume 168) by Roger G. Pertwee (Editor) The present book is an outstanding summary of many aspects of cannabinoid research. It provides current knowledge about the pharmacology and therapeutic potential of cannabinoids as well as knowledge about the pharmacology, physiology, and pathology of the endogenous cannabinoid systems. The chapters are written by scientists who have made or are still making major contributions to the field. This book may well help generate novel ideas on how to approach the study of emotions. |
 |
Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential by Ethan B Russo (Author) Presents an objective and comprehensive description of the state of the art of medicinal cannabis. Contains new and updated data based on international sources. Hardcover, softcover also available. |
 |
Medicinal Uses of Cannabis and Cannabinoids by Geoffrey W. Guy (Editor), Brian A. Whittle (Editor), Philip J. Robson (Editor) In recent years, cannabis research has moved beyond its use as an illegal recreational drug to consider its potential as a therapeutic substance, particularly in serious chronic illnesses such as multiple sclerosis. Although there is a considerable body of primary literature relating to the medicinal use of cannabis, much of the published work concerns anecdotal reports. This title describes all the contemporary research findings relating to the medicinal use of cannabis and cannabinoids, and reports on the pharmacology, formulation, safety and efficacy of cannabis as a therapeutic agent. This should be a useful reference for pharmacists, doctors, pharmacologists and all other healthcare professionals with an interest in pain control. |
 |
Cannabinoids and the Brain by Attila Köfalvi (Author), Attila Köfalvi (Editor) Endocannabinoids control most of the body functions, and in the brain, they modulate neurotransmission, synaptic plasticity, confer neuroprotection, control metabolism, neuro- and neuritogenesis, survival, cognitive and motor functions as well as a plethora of other higher-order brain functions. Their fruitful therapeutic potential is recognized by cannabinoid researchers and pharmaceutical companies, respectively. The aim of this book is to help clinicians, neuroscientists, as well as students, understand the significance of the endocannabinoid system. This book, however, also will be very useful to those who already feel comfortable with the neuroscience of endocannabinoids. The book will introduce the reader to the up-to-date neurobiology of endocannabinoids and related... |
 |
Cannabinoids as Therapeutics (Milestones in Drug Therapy) by Raphael Mechoulam (Editor) In recent years, cannabis research has concentrated on the potential of cannabinoids as therapeutic substances, particularly in serious chronic illnesses such as multiple sclerosis. Most volumes published on cannabinoids so far concentrate on the biological activity, biochemistry and pharmacology, whereas this volume concentrates on the diseases, the physiological effects and therapeutic use of cannabinoids. The volume editor Prof. Mechoulam was the first who isolated the prime active constituent (THC, Tetrahydrocannabiol) of marijuana. He published extensively on the pharmacological activities of cannabinoids. The volume is of interest to researchers and clinicians from pharmacology, neuroscience, and medicinal research. |
 |
The Cannabinoid Receptors (The Receptors) by Patricia H. Reggio (Editor) As research has progressed, the cannabinoid CB 1 and CB 2 receptors have expanded significantly in importance within the neuroscience mainstream. In The Cannabinoid Receptors, leading experts introduce newcomers to the cannabinoid field with chapters covering cannabinoid ligand synthesis and structure activity relationships, the molecular pharmacology of the cannabinoid receptors and the endocannabinoid system, and ultimately, the whole animal pharmacology and therapeutic applications for cannabinoid drugs. Adding to those key topics, the book also examines the current direction of the field with chapters on new putative cannabinoid receptors and challenges for future research. As a part of The Receptors ™ series, this volume highlights its receptor with the most thorough, focused... |
 |
Cannabinoids in Nature and Medicine by Didier M. Lambert (Editor) Originally a special issue of Chemistry & Biodiversity, the first part of this volume focuses on the plant Cannabis sativa, its active ingredients, and the discovery of cannabinoid receptors as well as the therapeutic applications of activating, or blocking, the receptors. Following an overview of the plant, its medicinal uses, and its preparations, further chapters cover biosynthetic pathways, pharmacological properties, cannabis-based medicine, toxicology, cannabis prohibition and clinical situations where blocking the cannabinoid receptors might be beneficial. The second part covers the journey from humans to plants, analyzing anandamide, as well as other endocannabinoids and endocannabinoid congeners, biosynthetic pathways, current knowledge of FAAH-1, FAAH-2, monoglyceride... |
 |
Marijuana and the Cannabinoids (Forensic Science and Medicine) by Mahmoud A. ElSohly (Editor) Marijuana and the Cannabinoids presents a compendium of research into the botany, chemistry, and pharmacology of cannabis and the medicinal aspects of the cannabinoids. While medicinal use of Cannabis sativa L. has been reported for over 5000 years, interest in its medicinal potential and controversy surrounding its illicit use have grown exponentially since the identification of the chemical structure of the plant's active constituent (D9-THC) in 1964. This volume presents the findings of researchers on the forefront of this emerging and controversial field of study. Chapter 1 is an overview of Cannabis and natural Cannabis medicines, while Chapter 2 focuses on the chemistry and analysis of phytocannabinoids and other Cannabis constituents. Chapter 3 discusses the potential of chemical... |
 |
Marijuana and Cannabinoid Research: Methods and Protocols (Methods in Molecular Medicine) by Emmanuel S. Onaivi (Editor) A cutting-edge collection of readily reproducible in vitro and in vivo methods to elucidate the mechanisms associated with cannabinoid function in health and disease. The techniques can be used in studies across the board from genes to behavior. The molecular neurobiological methods are invaluable in analyzing the structure, the polymorphisms, and the molecular expression of the cannabinoid receptors (CBrs), as well as their association with polysubstance abuse. There are also methods for localizing cannabinoid receptors in different systems, visualizing cannabinoid effects using brain slice imaging and elctrophysiological approaches, and designing and synthesizing cannabinoids and endocannabinoids. The protocols follow the successful Methods in Molecular Medicine™ series format, each... |
 |
Cannabinoids (Neuroscience Intelligence Unit) by Vincenzo Di Marzo (Editor) The 21st century will witness the unprecedented marketing of therapeutic drugs developed from cannabinoids and the endocannabinoid system. Cannabinoids is a timely volume, which represents a comprehensive review of the most important issues in cannabinoid research as well as those of most likely therapeutic relevance. For the first time, the multi-faceted aspects of cannabinoid chemistry, biology and medicine are presented in one volume. Key topics of discussion: major families of phytocannabinoids; pharmacological activity of phytocannabinoids; interactions of phytocannabinoids with their proposed molecular target; components of the endocannabinoid system; molecular mechanisms of the endocannabinoid system; Physiological and pathological role of endocannabinoids; industrial... |
| © 2009 BrightSurf.com |